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a  b  s  t  r  a  c  t
HSP90  is a multi-client  chaperone  involved  in  regulating  a large  array  of cellular  processes  and  is  com-
monly  overexpressed  in  many  different  cancer  types  including  hematological  malignancies.  Inhibition  of
HSP90  holds  promise  for targeting  multiple  molecular  abnormalities  and  is therefore  an  attractive  target
for heterogeneous  malignancies  such  as  Acute  Myeloid  Leukemia  (AML).
Ganetespib  is a highly  potent  second  generation  HSP90  inhibitor  which  we  show  is  signiﬁcantly  more
effective  against  primary  AML  blasts  at nanomolar  concentrations  when  compared  with  cytarabine
(p  <  0.001).  Dose  dependant  cytotoxicity  was  observed  with  an apoptotic  response  coordinate  with  the
loss of pro-survival  signaling  through  the client  protein  AKT.  Combination  treatment  of primary  blasts
with  ganetespib  and  cytarabine  showed  good  synergistic  interaction  (combination  index  (CI):  0.47)  across
a range  of drug  effects  with  associated  reduction  in HSP70  feedback  and  AKT  signaling  levels.
In summary,  we  show  ganetespib  to have  high  activity  in  primary  AMLs  as a  monotherapy  and  a  syner-
gistic  relationship  with  cytarabine  when  combined.  The  combination  of  cytotoxic  cell death,  suppression
of  cytoprotective/drug  resistance  mechanisms  such  as  AKT  and  reduced  clinical  toxicity  compared  to
other HSP90  inhibitors  provide  strong  rationale  for the  clinical  assessment  of  ganetespib  in AML.
© 2015  The  Authors.  Published  by  Elsevier  Ltd.  This  is  an  open  access  article  under the  CC  BY license. Introduction
Heat shock protein 90 (HSP90) is a key member of the heat
hock protein family which act as molecular chaperones, facilitat-
ng protein folding and activation of client proteins that cover a
iverse range of cellular functions including signal transduction
ia protein kinases, chromatin/epigenetic remodeling, vesicular
ransport, immune response, steroid signaling and regulation of
iral infections [1–3]. HSP90 is abundantly expressed in eukaryotic
ells with both constitutive and stress induced isoforms [4] and is
ften associated in complex with HSP70 and co-chaperones such
s HSP40 and Cdc37 [5], which aid in client protein binding, ATP
ediated activation and protection from proteosome degradation
6,7].
HSP90 overexpression has been reported in several malig-
ancies [8–10] including hematological malignancies such as
ML where overexpression has been linked with poor prognosis
3,11,12]. HSP90 acts as a chaperone to a large number of client
roteins including SRC, KIT, RAL, JAK, AKT, ERBB2 and CDKs, many
f which are oncogenically activated in cancer cells [13]. Drug
∗ Corresponding author. Tel.: +44 02921 848630; fax: +44 02920 744655.
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resistance, cell survival and tumor progression may  be critically
dependent upon HSP90 function through the chaperones ability to
protect mutant and oncogenic proteins from degradation. Given the
molecular heterogeneity of AML, HSP90 inhibition could represent
a logical therapeutic strategy.
Initial targeting of HSP90 focused on geldanamycin, a large nat-
urally occurring compound and its ansamycin derivatives 17-AAG
and 17-DMAG which mimicked the ATP binding site of HSP90 [14].
Therapeutic activity was observed in many malignancies [13], how-
ever poor pharmacological properties and toxicities limited their
further progress [15]. Ganetespib belongs to the resorcinol group of
second generation synthetic HSP90 inhibitors which are consider-
ably smaller and work by competitively binding the N-terminal ATP
binding site. Pre-clinical studies have shown ganetespib to have
greater potency than ﬁrst generation inhibitors such as 17-AAG
in several cancers [16–18], including hematological malignancies
[19]. It has also been shown to also overcome tyrosine kinase
inhibitor (TKI) resistance [18]. Clinically, ganetespib has shown a
favorable safety proﬁle without the dose-limiting liver or ocular
toxicities associated with other Hsp90 inhibitors [20,21], and has
shown encouraging activity in a Phase 2 NSCLC trial [22]. As a pre-
lude to clinical studies we  assessed the in vitro effects of ganetespib
in AML  cell lines and primary AML  blasts both as a single agent and
in combination with cytarabine.
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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. Materials and methods
.1. Samples and cell culture
Bone marrow and peripheral blood samples were collected from newly
iagnosed AML  patients entering the NCRI AML15, 16 and 17 trials with the
atients’ informed consent using documentation approved by the Wales Multicentre
esearch Ethics Committee. The clinical characteristics of the 52 patients are shown
n  Table 1. Primary mononuclear cells were enriched by density gradient centrifuga-
ion with Histopaque (Sigma, Poole, UK) and further analyzed for blast (leukaemic
ell) purity by CD45 staining and ﬂow cytometry. AMLs with >70% blasts following
radient fractionation were cryopreserved and used for subsequent analysis. HL60
ells were maintained in RPMI media supplemented with 10% fetal bovine serum
FBS). MV411 cells and primary AML  blasts were cultured in IMDM media supple-
ented with 10% FBS. All cultures were maintained at 37 ◦C in a 5% CO2 humidiﬁed
tmosphere. Cell viability was  measured by trypan blue exclusion on a Cellometer
ision (Peqlab Ltd., Fareham, UK).
.2. Cell viability assays
In vitro cytotoxicity assays were performed in 96 well plates on cell lines
nd primary material using the CellTiter96® Aqueous one solution cell prolifer-
tion assay(MTS) according to the manufacturer’s instructions (Promega UK Ltd.,
outhampton, UK). Primary cells (1 × 105/well) and cell lines (1 × 104/well) were
reated with serial dilution dose range of ganetespib or cytarabine (AraC) in triplicate
nd IC50 values calculated using Calcusyn software (Biosoft, Cambridge, UK).
Synergy between ganetespib and Ara-C was assessed in cell lines and primary
ML  samples using an experimentally determined ﬁxed molar ratio of ganetespib
ith AraC within clinically relevant doses (1:100, 1:50, 1:10 ratios). Drugs were
et up singly and in combination and Calcusyn software was used to determine
ombination index (CI) values according to the Chou and Talalay method [23]. CI
alues of <1 were considered synergistic..3. Flow cytometric analysis of apoptosis
HL60 and NB4 AML  cell lines were treated with ganetespib at concentrations
etween 10 and 250 nM,  and cultured for 24 h, 48 h and 72 h. Annexin V positivity
ig. 1. Ganetespib shows improved efﬁcacy compared to AraC in AML. Dose response cu
y  MTS  cell proliferation assay (% survival calculated compared to equivalent vehicle con
n  = 22). (D) AraC efﬁcacy in primary cohort at 48 and 72 h. *Ganetespib vs AraC EC50 p < 0earch 39 (2015) 617–624
was measured using the Annexin V Apoptosis Detection Kit (eBioscience, Hatford,
UK)  according to the manufacturer’s instructions. Brieﬂy, cells were washed in phos-
phate buffered saline (PBS) and incubated with ﬂuorescein-labeled Annexin V for
10 min. Cells were then washed and resuspended in 1 g/ml propidium iodide (PI)
prior to assessment by ﬂow cytometry (Accuri Cytometers (Becton Dickinson, UK)).
All experiments were performed in triplicate.
2.4. Immunoblotting
AML cells were treated with increasing doses of ganetespib for 48 h and washed
3  times in ice-cold phosphate-buffered saline (PBS) then lysed in 20 mM Tris [pH
7.4], 150 mM NaCl, 1% Igepal (Sigma–Aldrich, Poole, UK), 10% glycerol, 10 mM EDTA,
20  mM NaF, and 3 mM NaVO4 plus complete protease inhibitors (MiniComplete
EDTA-free; Roche, Burgess Hill, UK) for 30 min  at 4 ◦C followed by centrifugation
at  16,000 × g. The clariﬁed protein lysates were quantiﬁed and subjected to West-
ern  blotting as previously described [24] using antibodies for HSP90, AKT, IKB
(Cell  Signaling Technology Inc., New England Biolabs, Hitchin, UK), HSP70 (Milli-
pore (UK) Ltd., Watford, UK). Blots were reprobed for equal loading using GAPDH
(Cell Signaling Technology Inc., New England Biolabs, Hitchin, UK) and quantiﬁed
using AIDA image analysis software (Raytest UK Ltd.).
3. Results
3.1. Ganetespib shows high potency in primary AML  samples
The cytotoxicity of ganetespib was initially assessed by MTS
assay using the myeloid cells lines MV411 and HL60. Analysis of
ganetespib dose response curves showed increased efﬁcacy com-
pared with cytarabine, with low nanomolar EC50s of 8.4 nM and
2.7 nM for HL60 and MV411 respectively (Arac EC50; 116 nM and
961 nM respectively) at 72 h (Fig. 1A and B). The main aim of the
project was  to assess sensitivity in primary samples which have
had various responses to conventional chemotherapy. Ganetespib
rves for (A) HL60 and (B) MV411 cells following drug exposure for 72 h measured
trol). (C) MTS  ganetespib drug efﬁcacy in primary AML  cells at 48 (n = 62) and 72 h
.0001 at 48 and 72 h. Ganetespib 48 vs 72 h p = 0.4.
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Table  1
Patient characteristics.
Characteristic Number (%) Median EC50 (nM)
and range
p-Value (relation
between EC50 and
characteristic)
All data 21.6 (1.4–272.9)
Triale 0.6b
AML15 21 (34%) 15.3 (4.5–106.8)
AML16 9 (15%) 22.6 (2.9–101.7)
AML17 30 (48%) 21.9 (1.4–272.9)
AML  LI-1 2 (3%) 47.2 (27.3–67.2)
Treatment regimen 0.2b
Intensive chemo 56 (90%) 21.1 (1.4–272.9)
Non-intensive 6 (10%) 45.4 (98.9–84.6)
Age (years) 0.06c
0–29 6 (10%) 17.1 (3.5–70.9)
30–39 7 (11%) 21.7 (4.5–58.3)
40–49 12 (19%) 14.9 (1.4–272.9)
50–59 4 (26%) 22.0 (5.6–106.8)
60+  21 (34%) 22.9 (2.9–116.2)
Median (range) 54 (0–88)
Sex 0.9b
Male 27 (44%) 21.7 (2.9–272.9)
Female 35 (56%) 21.4 (1.4–106.8)
WBC  0.5c
0–9.9 2 (3%) 13.9 (6.4–21.4)
10–49.9 28 (45%) 23.6 (2.9–101.7)
50–99.9 15 (24%) 44.6 (1.4–272.9)
100+ 17 (27%) 15.3 (4.0–44.7)
Unknown
Median (range) 55.0 (7.5–249.0)
Type of AML  0.13b; 0.2d
De Novo 54 (87%) 21. 6 (1.4–272.9)
Secondary 7 (11%) 50.8 (4.5–116.2)
MDS  1 (2%) 2.9
FAB  group 0.3b
M0 0
M1  7 (16%) 21.7 (6.4–66.0)
M2  6 (13%) 37.9 (11.8–101.7)
M4  17 (38%) 21.4 (1.4–272.9)
M5  15 (33%) 14.9 (3.5–116.2)
Unknown/other 17
Cytogenetic group 0.07c
Favorable 4 (8%) 52.8 (4.5–272.9)
Intermediate 46 (88%) 19.8 (1.4–116.2)
Adverse 2 (4%) 9.5 (4.0–14.9)
unknown 10
WHO  performance statusa 0.8c
0 31 (51%) 21.4 (2.9–272.9)
1  25 (41%) 25.1 (4.5–116.24)
2  2 (3%) 34.3 (1.4–67.2)
3  3 (5%) 20.7 (15.3–21.7)
FLT3 status 0.9b
ITD wt 35 (58%) 22.9 (2.9–272.9)
ITD  mutant 25 (42%) 20.7 (1.4–116.2)
ITD  unknown 2
TKD wt 52 (90%) 0.7b
TKD mutant 6 (10%) 21.1 (1.4–272.9)
TKD unknown 4 24.7 (13.5–58.3)
NPM1 status 0.3b
WT 31 (53%) 17.3 (2.9–272.9)
Mutant 28 (47%) 21.9 (1.4–106.8)
Unknown 3
a One pediatric patient did not complete the WHO  performance status cscale and instead completed the play performance scale.
b Wilcoxon Rank-Sum/Kruskal–Wallis test for difference between groups.
c Spearman correlation coefﬁcient for continuous data/ordered groups.
d Test for secondary vs not secondary disease.
e Trials AML15, 16 and 17 patients were treated intensively (2 rounds of either: ADE (daunorubicin, cytarabine, etoposide), DA/DAT (daunorubicin, cytarabine/daunorubicin,
cytarabine, thioguanine), FLAG-Ida (ﬂudarabine, cytarabine, idarubicin, G-CSF) followed by two rounds of consolidation/novel agents,follow-up complete to 1/1/2014). AML16
non-intensive and LI-1 received low dose cytarabine based therapy. Apoptotic response in cell lines and primary samples.
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ctivity at 48 h was then assessed in primary blasts isolated from
iagnostic AML patients (n = 62). Ganetespib was signiﬁcantly more
otent than AraC in primary blasts with an EC50 of 20.9 ± 21 nM and
.4 ± 7 M respectively (p < 0.001, MWU,  Fig. 1C and D). There was
o signiﬁcant improvement in ganetespib activity at 72 h (p = 0.4,
WU,  n = 22) compared with a 48 h assessment, so further drug
nalysis was carried out using the 48 h time point.
To assess the clinical correlations associated with in vitro drug
ensitivity, we studied the relationship between clinical outcome
n patients treated with conventional intensive chemotherapy
n relation to log10(EC50) of ganetespib (Patient and treatment
etails, Table 1). There was no signiﬁcant association with patients
ig. 2. Ganetespib induces dose dependant induction of apoptosis. Apoptotic induction o
8  and 72 h by ﬂow cytometry. All experiments were performed in triplicate. (C) Exam
esponse. (D) Primary cell AnnexinV/PI induction following ganetespib dosing over a 24 hearch 39 (2015) 617–624
characteristics, although there was  a trend for higher EC50 levels to
be associated with higher age. Survival data was  available on 54/56
intensively treated patients. We  found no signiﬁcant association
between EC50 and relapse risk or survival when analyzed with
EC50 (OR 1.02 (0.20–5.30) per 10-fold increase in EC50, p = 1.0) or
relapse free survival (HR 1.31 (0.55–3.10) per 10-fold increase in
EC50, p = 0.6) or overall survival (HR 1.73 (0.84–3.55) per 10-fold
increase in EC50, p = 0.13) in univariate analyses. In analyses
adjusted for age, WBC, performance status, secondary disease and
cytogenetics, however, there was  some evidence that higher EC50
may  be associated with a trend for worse survival although this
did not reach signiﬁcance (HR 2.53 (0.94–6.77) p = 0.07). This data
f Annexin V/PI incorporation in (A) HL60 and (B) MV411cell lines measured at 24,
ple ﬂow cytometry data of dual Annexin V/PI staining of MV411 cells at maximal
 and 48 h period.
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uilds a rationale for taking ganetespib into the clinic as it can
otentially target cells from all AML  patients equally, even those
ho did poorly with conventional chemotherapy.
Annexin V/PI incorporation was investigated by ﬂow cytometry
o conﬁrm a cytotoxic method of action for ganetespib in AML  over
 time course of 24, 48 and 72 h. AML  cells showed a dose and time
ependant increase in apoptotic induction in response to ganete-
pib (Fig. 2A–C). This effect was also observed in primary AML  cells
Fig. 2D).
.2. HSP90 targeting with ganetespib results in client protein
egradation
Ganetespib treated AML  blasts were subjected to Western blot
nalysis for HSP protein response and client protein knockdown
ig. 3. Primary AML  blasts show client protein knockdown following ganetespib treatm
reatment. Quantiﬁcation of (B) HSP90 n = 10, (C) HSP70 n = 6, (D) AKT n = 6, protein expr
o  GAPDH protein levels and expressed as a percentage or fold change relative to untreatearch 39 (2015) 617–624 621
(Fig. 3A). Although total levels of HSP90 protein were maintained
following blast incubation with ganetespib (n = 10), a dose depen-
dant increase in the chaperone protein HSP70 was seen at 48 h
(Fig. 3B and C). Given that the use of HSP90 inhibitors may block
pro-survival resistance mechanisms in AML  blasts such as AKT
overexpression, quantitation of AKT levels following ganetespib
exposure was performed in a cohort of primary AML  cells (n = 6)
and results show a dose dependant loss of AKT expression (Fig. 3D).
3.3. Ganetespib shows synergistic action with cytarabineCytosine arabinoside is a standard agent for leukemia and
produces remission rates of 25–80% when used in a high-dose inter-
mittent schedule in AML  relapse. Given that DNA repair proteins
can lessen the activity of cytarabine and several of these factors
ent. (A) Representative western blot of primary AML  48 h following ganetespib
ession in response to increasing doses of ganetespib. All samples were normalized
ed samples.
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Fig. 4. Ganetespib synergizes with AraC. (A) Combination index (CI) values were calculated between ganetespib and AraC in myeloid cell line HL60 at a 1:250 molar ratio (B) CI
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talues  for primary AML  samples (n = 15) at 1:10 ratio (ganetespib:AraC). A CI value o
n  response to increased drug effect (D) representative Western blot of primary AM
nalysis of fold change relative to untreated control is expressed below each panel.
re HSP90 client proteins [25], we assessed whether ganetespib
ould enhance the activity of cytarabine in AML  blasts and AML
ell lines. Synergistic ratios between the two agents were ﬁrst
ssessed in AML cell line HL60 (Fig. 4A) using serial dilutions of ﬁxed
olar ratios and then in a cohort of primary AML  blasts (n = 15).
s the efﬁcacy of cytarabine in primary blasts is reduced, ratios
f 1:10, 1:50 and 1:100 were investigated. Combination index (CI)
alues were established for each patient and ganetespib showed
ood synergy with cytarabine (CI ave = 0.47) at a 1:10 dose ratio
cross a range of dose effects (Fig. 4B–D). Western blot analysis of
ombination treated AML  blasts showed a small increase in client
rotein AKT knockdown and also interestingly, up regulation of
KB (a repressor of the pro-survival protein NFB known to con-
er drug resistance in AMLs [26]) and reduced HSP70 induction
n response to combination treatment compared to an equivalent
ose of ganetespib alone.
. Discussion
This study demonstrates that the novel HSP90 inhibitor, ganete-
pib, is an effective agent against primary AML  blasts at nanomolar
oncentrations which are clinically achievable [21] and far supe-
ior to the standard agent, cytarabine. Previous studies of HSP90
nhibition have shown similar anti-proliferative effects in AML  and
ther leukaemias [27–30], although ganetespib exhibits consider-
bly greater potency than has been reported with previous HSP90
gents in primary AML  samples [3,30]. The clinical development of
any HSP90 inhibitors has been limited by toxicities, particularly
cular toxicity [13,29], but the clinical development of ganetespib
o date suggests that the drug is well tolerated and that the ocular indicative of synergy between the agents. (C) Representative data showing CI range
wing ganetespib target effects alone and in combination with AraC. Densitometry
toxicity is infrequent, in contrast to some other second generation
HSP90 inhibitors [16,20,21].
Induction of dose dependent apoptosis was observed in AML
cells indicating a cytotoxic method of cell death in response to treat-
ment. Annexin induction of cell death occurred at slightly higher
drug doses than observed for the MTS  assay and this may  be par-
tially due to the action of ganetespib on cell cycle regulator clients
of HSP90. Ganetespib has already been shown to induce growth
arrest and apoptosis in several other cancer models [18,31,32].
Although total HSP90 protein levels remained unchanged by
HSP90 inhibition (in line with previous reports [33]), we demon-
strated client protein knockdown at nanomolar doses of the
pro-survival kinase AKT, which has been previously reported to
mediate drug resistance and poor prognosis in AML  [34]. AKT is just
one of a number of client proteins (known or unknown) for HSP90
that may  be targeted by ganetespib treatment and knockdown of
multiple HSP90 clients such as KIT, Ral, JAK2 and members of the
CDK family [5] may  contribute to the observed high efﬁcacy of this
drug in primary AML  samples. Concurrently we observed upregu-
lation (although transient) of the chaperone HSP70 by ganetespib.
This upregulation of HSP70 by HPS90 inhibitors has been reported
as a cytoprotective function in response to HSP90 inhibition with
sustained induction of the HSP transcription factor HSF1 driving
a potential feedback mechanism by which other HSPs are also
upregulated [6]. Induction of HSP70 has been reported to lead to
drug resistance and poor prognosis in several cancer types [35–38]
including AML  [9]. It has also been previously used as a readout
of HSP90 inhibitor action in the clinic [11,39], including initial
ganetespib studies [21]. Knockdown of HSP70 using pharmacologi-
cal inhibitors increases the efﬁcacy of HSP90 inhibition in AML  [40],
however several time course studies report HSP70 upregulation as
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ransient and diminishing with disease progression and may  not
redict patient outcome [6,9], suggesting a limited role for HSP70
s a biomarker of response.
Previous reports show HSP90 knockdown can sensitize cells
o DNA damage inducing agents [41] providing good rationale for
ombination therapy. However, as HSP90 inhibition can cause cell
ycle arrest, there may  be concerns about combination with S-
hase inhibitors such as cytarabine. Our pre-clinical data suggest
anetespib and cytarabine combination shows good synergistic
nteraction when co-administered in vitro at a range of clinically
elevant doses including those used in the recent Li-1 trial. This
ata is in line with previous combination studies in myeloma cells
here co-administration rather than sequential dosing of agents
iving maximum synergistic effects [36]. Our combination data also
hows reduced HSP70 induction compared to ganetespib alone,
educing the possible resistance issues associated with induction
f this chaperone. This supports the rationale for clinical develop-
ent of ganetespib in combination with the standard cytarabine
herapy as has been initiated in ISRCTN40571019.
Given the redundancy of many protein kinases in tumor mainte-
ance, the effectiveness of any inhibitor may  rely on the oncogene
ddiction to the HSP90/client protein [42]. The multi-client action
f HSP90 affords ganetespib the ability to inhibit many more tar-
ets than typical kinase inhibitors, and in combination with other
hemotherapeutic and novel agents will allow ganetespib maxi-
um  targeting of diverse molecular abnormalities such as those
ound in AML.
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